UTROL Capsules

INDICATIONS:

1: ANAEMIA
2: LEUORRHOEA
3: MENORRHAGIA
4: GENERAL DEBILITY
5: HABITUAL ABORTION
6: NON SPECIFIC VAGINITIS
7 : MALE & FEMALE INFERTILITY
COMPOSITION: 

Constituents
Faulad
Momiai
Oyster Shell
Gum Acacia
Butea Frondosa
Emblica Officinalis
Cinnamomum Cassia
Elettaria Cardamomum

Active Ingredients
Iron (Herbal Processed)
Benzoates, Mminerals, Icthyol
Calcium
Arabic Acid
Glucosides
Vitamin-C, Minerals
Cinnamic acid, Volatile oil
Terpinyl acetate
DESCRIPTION:
Utrol is a specified combination of natural astringents, anti spasmadics and anti microbials so check leucorrhoes, non-specific vaginitis and menorrhagia. Cardamomum in Utrol, a source of terpinyl acetate nausea, vomiting, headache and acts as a refrigerant.
Utrol contaions herbal processed iron, Emblica - the richest source anaemia, general debility and calcium Deficiency
Regular use of Utrol restores normal function of the uterus, imparts vigour to the uterine system and thus minimizes the chances of habitual abortion. The role of Utrol as a supportive therapy is highly appreciable in female infertility provided this infertility is not due to surgical indications. Like wise the role of Utrol as a supportive therapy in male infertility is also considerable where it helps in increasing the percentage of alive sperms and their motility.

Side Effects:
Very few number of patients may suffer mild constipation that can be relieved with the use of milk or excessive quantity of water.

Dosage:
In leucorrhoea, non-specific vaginitis and menorrhagia one capsule of Utrol B.D (twice a day) with milk for one month. In anaemia and general debility one capsule of Utrol O.D (once daily) with milk for one month.
In habitual abortion, male & female infertility one capsule of Utrol B.D (Twice a day) for 3 months as a supportive therapy. In pregnancy one capsule of Utrol O.D (one daily) throughout pregnancy.

Packing:
One pack of 20's capsules.

Contact us
+923451696400
myfirstwab0@gmail.com

         Zerifax (Rifaximin) 200mg/550mg

Zerifax

                     FEBUXIN (Febuxostat)

            CALAMOX Drops 10ml

         ABAPEN 100mg Capsules

CLINICAL PHARMACOLOGY:
Mechanism of Action:
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose
Distribution:
Dapagliflozin is approximately 91% protein bound. Protein binding is not altered in patients with renal or hepatic impairment.
Metabolism:
The metabolism of dapagliflozin is primarily mediated by UGT1A9; CYP
Elimination:
Dapagliflozin and related metabolites are primarily eliminated via the renal pathway. Following a single 50 mg dose of [14C]-dapagliflozin, 75% and 21% total radioactivity is excreted in urine and feces, respectively. In urine, less than 2% of the dose is excreted as parent drug. In feces, approximately 15% of the dose is excreted as parent drug. The mean plasma terminal half-life (t½) for dapagliflozin is approximately 12.9 hours following a single oral dose of 10 mg.
Pharmacokinetics in special populations:
Renal Impairment:
The steady-state 24-hour urinary glucose excretion in patients with type 2 diabetes and mild, moderate, and severe renal impairment was 42%, 80%, and 90% lower, respectively, than patients with type 2 diabetes with normal renal function. The impact of hemodialysis on dapagliflozin exposure is not known.
Hepatic Impairment:
In patients with severe hepatic impairment (Child-Pugh class C), mean Cmax and AUC of dapagliflozin were up to 40% and 67% higher, respectively, as compared to healthy matched control.
Effects of Age, Gender, Race, and Body Weight on Pharmacokinetics:
Based on a population pharmacokinetic analysis, age, gender, race, and body weight do not have a clinically meaningful effect on the pharmacokinetics of dapagliflozin and thus, no dose adjustment is
Pediatric:
Pharmacokinetics in the pediatric population is not known.
INDICATIONS AND USAGE:
XIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Limitation of Use:
XIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
DOSAGE AND ADMINISTRATION:
Administration: 
The recommended starting dose of XIGA is 5 mg once daily, taken in the morning, with or without food. In patients tolerating XIGA 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of XIGA is recommended.
DOSE MODIFICATION

Insulin and insulin secretagogues are known to cause hypoglycemia. XIGA can increase the risk of
hypoglycemia when combined with insulin or an insulin secretagogue. Therefore, a lower dose of
insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these
agents are used in combination with XIGA.
Genital Mycotic Infections:
XIGA increases the risk of genital mycotic infections. Patients with a history of genital mycotic
infections were more likely to develop genital mycotic infections.
Increases in Low-Density Lipoprotein Cholesterol (LDL-C):
Increases in LDL-C occur with XIGA. Monitor LDL-C and treat per standard of care after initiating
XIGA.
Bladder Cancer:
XIGA should not be used in patients with active bladder cancer. In patients with prior history of bladder cancer, the benefits of glycemic control versus unknown risks for cancer recurrence with
XIGA should be considered.

Macrovascular Outcomes:
Conclusive evidences of macrovascular risk reduction with XIGA or any other antidiabetic drug are insufficient.
DRUG INTERACTIONS:
Positive Urine Glucose Test:
Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.
Interference with 1,5-anhydroglucitol (1,5-AG) Assay:
Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5 AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

USE IN SPECIFIC POPULATION:
Pregnancy:
Pregnancy Category C:
During pregnancy, consider appropriate alternative therapies, especially during the second and third trimesters. XIGA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:
It is not known whether XIGA is excreted in human milk, but because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from XIGA, a decision should be made whether to discontinue nursing or to discontinue XIGA, taking into account the importance of the drug to the mother.
Pediatric Use:
Safety and effectiveness of Dapagliflozin in pediatric patients under 18 years of age have not been established.
Renal Impairment:
Based on its mechanism of action, XIGA is not expected to be effective in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2) or ESRD.
Hepatic Impairment:
The benefit-risk for the use of dapagliflozin in patients with severe hepatic impairment should be individually assessed since the safety and efficacy of dapagliflozin have not been known in this population.
ADVERSE REACTIONS:
Specific:
Hypotension, Impairment in Renal Function, Hypoglycemia with Concomitant Use with Insulin and
Insulin Secretagogues, Genital Mycotic Infections, Increases in Low-Density Lipoprotein
Cholesterol (LDL-C), Bladder Cancer.

Allergic Reaction:
Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) serious anaphylactic reactions and severe cutaneous adverse reactions and angioedema were reported at 0.2% Dapagliflozin-treated patients. If hypersensitivity reactions occur, discontinue use of XIGA; treat
per standard of care and monitor until signs and symptoms resolve.

Laboratory Tests:
Increase in Hematocrit, Increase in Serum Inorganic Phosphorus, Increase in Low-Density Lipoprotein Cholesterol.

OVERDOSAGE:
In the event of an overdose, contact the Poison Control Center. It is also reasonable to employ supportive measures, as dictated by the patient’s clinical status.

INSTRUCTIONS:
- Store below 30ºC.
- Protect from heat, sunlight & moisture.
- Keep out of the reach of children.
- To be sold on the prescription of a registered medical practitioner only.

PRESENTATION:
Xiga Tablet 5 mg : Pack of 2x7 tablets.

Xiga Tablet 10 mg : Pack of 2x7 tablets.

                           Relaxin 3 mg

COMPOSITION
each tablet contains:
Bromazepam.........................3 mg

CHEMISTRY
Chemical name of Relaxin is 7-bromo-1, 3-dihydro-5(2-pyridyl)-2H-1,4-benzodiazepin-2-one(bromazepan) and its structural formula is shown below.

INTRODUCTION
Relaxin is a pyridybenzodiazopine derivativ as a potent psychotronic agent. It selectively reduces tension and anxiety where as in high doesage it shown sedative and muscle relaxing properties.

INDICATIONS
Relaxin is indicated for the short term treatment of tension, anxiety, emotional disturbances, agitation and insomia, anxious agitated depressive reactions. Functional disturbances in the cardio vascular and respiratory systems (pseudoangina pectoris precordial anxiety techycardia, emotiogenic hypertension, dyspnea; hyperventilation, psychosomatic disorders, psychogenic, heaache, psychogenic dematosis and asthma.)

CNTRAINDICATIONS
patients with known sensitivity to bonzodiazepines, acute pulmonary in sufficiency, respiratory depression, myastheina gravis. Bromazepam shod be avoided during pregnancy. The administration of high doses or porlonged administration of low doses of bonzodiazepines in the last trimester of pregnancy or during labour has been reported to produce irregularities in the foetal heart reate and hypotonia, poor sucking and hypothermia in the neonates.

DOSAGE AND ADMINISTRATION
Adults: The optimum dosage and frequency of administration of Relaxin should be based on the individual patient, the severity of symptom and previous psychotropic drug history.

The usual dosage in general practice is from half to one tablet three times daily. In severe cases especially in hospitalized patients two to four tablets tow to three daily. In exceptional circumstances upto the maximum daily dosage of 60 mg in dividad doses, may be given.

After about three to six week, according to progreess in therapy, dosege can ususally gradually be redued and then stopped.

Children: Relaxin is not for paediatric use.

PRESENTATION
tablets: 3 x 10 Blister pack

Nuberol Forte Tablets

(paracetamol BP 650 mg + Orphenadrine Citrate BP 50 mg)

BRIEF PRESCPIBUNG INFORMATION

PROPERTIES
Nuberol is a muscle relaxant with analgesic.

PRESENTATION AND COMPOSITION
Nuberol is white round shaped, engraved 'SEARLE' on one side each tablet contains Paracetamol BP 450mg and Orphenadrine Citrate BP 35mg.

Nuberol Forte is white, oblong scored tablets stamped stamped searle on one side each containing Paracetamol BP 650mg and Orphenadrine Citrate BP 50mg.

Pharmacology:
The combined analgesic effect of Paracetamol and muscle relaxant action of Orphenadrine Citrate provides in-depth relief from pain associated with skeletal muscle spasm.

Paracetamol possess analgesic and antipyrrtic action similar to those of the salicylates.

Analgesia is mediated peripherally and also centrally.

Paracetamol is a synthetic derivative of p-aminophenol with analgesic and antipyretic activity but on anti-inflammatory action. Its plasma half-life is about 2 hours. It is extensively metabolized in the liver and subsequently excreted in the urine.

Orphenadrine Citrate is an orally effective muscle relaxan. The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense muscles in man. Orphenadrine citrate also possesses anti-cholinergic actions. Muscle relaxation is not due to a direct action on the muscle itself; rather the site of ection of Orphenadrine citrate is contral. Orphenadrine is readily absorbed from the gastro-intesinal tract and is almost completely metabolized to at least 8 metablites.

It is mainly excreted in the urine as metabolised and unchanged drug.

Indications:
For the relief of painful skeletal muscle spasm associated with chronic low back pain, spranins, strains, prolapsed intervertebbral disc, muscle injury, non-articular rheumatism, and tension headache, dysmenorrheal and other acute or chronic painful muscular conditions.

Contraindication:

Paracetamol:
Hypersensitivy to paracetamol, Repeated administration is contraindicated in patients with hepatic insufficientcy.

Orphenadrine citrate:
It is contraindicated in patients hypersensitive to Orphenadrine citrate. Orphenadrine should not be given to patientsvof myasthenia gravis, glaucona, urinary retention or lactating woman.

Dosage and Administration:

Nuberol:    Adults   : 1-2 tablet 3-4 times/day
                   Children : Not recommended.

Nuberol Fort:  Adults  : 1 tablet twice daily
                        Children : Not recommended.

Overdosage:

In overdosage Paracetamol is dangerously hepatotoxic; potentially falal hepatic necrosis can occur after ingestion of as little as a single dose of 10-15 g. Signs of mild gastrointestinal irritation are commonly followed 2 day later by anorexia, nausea, malaise, abdominal pain, progressive evidence of liver failure and, ultimately, hepatic come. Either methionone or ecetylcysteine may be used as a specific antidote. Fluid and electrolyte balance must be maintained and ventilation must be assisted when respiration is depressed.

Orphenadrine is toxic when overdosed and typically induces Anti-cholinergic effects.

Zolanix

(Fluconazole) 150 mg Capsule

COMPOSITION: each capsule contains 150 mg of fluconazole.

INDICATIONS:

ZOLANIX is indicated in adults for the treatment of the following fungal infection:
Cryptococcal meningitis, coccidioidomycosis, invasive candidiasis, mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis, chronic oral atrophic candidiasis if dental hygiene or topical treatment are insufficient, (vaginal candidiasis, acute or recurrent and candidal balanitis (when local therapy is not appropriate)), dermatomycosis including  tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated and tinea unguinium when other agents are not considered appropriate.
Also for prophylaxis of relapse of: cryptococcal meningitis, oroharyngeal or oesophageal candidiasis, recurrent vaginal candidiasis and candidal infection in patients with prolonged neutropenia.

DOSAGE AND ADMINISTRATION
Adults and adolescents: Cryptococcosis: 4 mg on day 1, subsequent dose: 200 mg to 400 mg daily. Inv asive candidiasi: 800 mg on day 1, subsequent dose: 400 mg daliy. coccidioidomycosis, treatment of mucosal candidiasis and prophylaxis of candidal infections in patintes with prolonged neutropenia: 200 mg to 400 mg. prevention of relapse of mucosal candidiasis in patients in fected with or risk of HIV: 100 mg 200 mg daily. genital candidiasis 150 mg as single dose. dermantomycosis: 150 mg once weekly.

CONTRACTIONS: Hypersensitivy to the active substance, or to of the excipients coadministration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYO) 3AA such as cisapride, astemizole, pimozide, quinidine and erythromycin. coadministration of terfenadine is contraindicated in patients receiving fluconazole at multiple doses of 400 mg per day or higher.

Pregnancy and Lactation: Fluconazole in high dose and/or in prolonged regimens should not be used during pregnancy except for potentially life-threatening infections. An observational study has suggested an increased risk of spontaneous abortion in woman treated with fluconazole during the first trimester. Breast-feeding is not recommended after repeated use or after high dose fluconazole.

OVERDOSAGE
Hallucinatin and paranoid behaviour have been concmitantly reported. In the event of overdose, symptomatic treatment (with supportive measures) may be adequate. A three-hour haemodialysis session decreases plasma level by approximately 50%. Further management should be as clinically indicated or as recommended by the national poisons canter, where available.